Vir Biotechnology Provides Corporate Update and Reports First Quarter 2023 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Vir Biotechnology Inc. (VIR) Misses Q1 EPS by 19c
May 4, 2023 4:50 PM EDTVir Biotechnology Inc. (NASDAQ: VIR) reported Q1 EPS of ($1.06), $0.19 worse than the analyst estimate of ($0.87). Revenue for the quarter came in at $63 million versus the consensus estimate of $51.58 million.
For earnings history and earnings-related data on Vir Biotechnology Inc. (VIR) click here.
... More